The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures : A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial
Copyright © 2023 Elsevier Ltd. All rights reserved..
BACKGROUND: Vaccines are urgently required to control Staphylococcus aureus hospital and community infections and reduce the use of antibiotics. Here, we report the safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine (rFSAV) in patients undergoing elective surgery for closed fractures.
METHODS: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial was carried out in 10 clinical research centers in China. Patients undergoing elective surgery for closed fractures, aged 18-70 years, were randomly allocated at a ratio of 1:1 to receive the rFSAV or placebo at a regimen of two doses on day 0 and another dose on day 7. All participants and investigators remained blinded during the study period. The safety endpoint was the incidence of adverse events within 180 days. The immunogenicity endpoints included the level of specific antibodies to five antigens after vaccination, as well as opsonophagocytic antibodies.
RESULTS: A total of 348 eligible participants were randomized to the rFSAV (n = 174) and placebo (n = 174) groups. No grade 3 local adverse events occurred. There was no significant difference in the incidence of overall systemic adverse events between the experimental (40.24 %) and control groups (33.72 %) within 180 days after the first immunization. The antigen-specific binding antibodies started to increase at days 7 and reached their peaks at 10-14 days after the first immunization. The rapid and potent opsonophagocytic antibodies were also substantially above the background levels.
CONCLUSIONS: rFSAV is safe and well-tolerated in patients undergoing elective surgery for closed fractures. It elicited rapid and robust specific humoral immune responses using the perioperative immunization procedure. These results provide evidence for further clinical trials to confirm the vaccine efficacy. China's Drug Clinical Trials Registration and Information Publicity Platform registration number: CTR20181788. WHO International Clinical Trial Registry Platform identifier: ChiCTR2200066259.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Vaccine - 41(2023), 38 vom: 31. Aug., Seite 5562-5571 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Xie-Yuan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.08.2023 Date Revised 06.09.2023 published: Print-Electronic ChiCTR: ChiCTR2200066259 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2023.07.047 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360164366 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360164366 | ||
| 003 | DE-627 | ||
| 005 | 20231226082428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2023.07.047 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360164366 | ||
| 035 | |a (NLM)37516573 | ||
| 035 | |a (PII)S0264-410X(23)00878-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Xie-Yuan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures |b A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.08.2023 | ||
| 500 | |a Date Revised 06.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ChiCTR: ChiCTR2200066259 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Vaccines are urgently required to control Staphylococcus aureus hospital and community infections and reduce the use of antibiotics. Here, we report the safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine (rFSAV) in patients undergoing elective surgery for closed fractures | ||
| 520 | |a METHODS: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial was carried out in 10 clinical research centers in China. Patients undergoing elective surgery for closed fractures, aged 18-70 years, were randomly allocated at a ratio of 1:1 to receive the rFSAV or placebo at a regimen of two doses on day 0 and another dose on day 7. All participants and investigators remained blinded during the study period. The safety endpoint was the incidence of adverse events within 180 days. The immunogenicity endpoints included the level of specific antibodies to five antigens after vaccination, as well as opsonophagocytic antibodies | ||
| 520 | |a RESULTS: A total of 348 eligible participants were randomized to the rFSAV (n = 174) and placebo (n = 174) groups. No grade 3 local adverse events occurred. There was no significant difference in the incidence of overall systemic adverse events between the experimental (40.24 %) and control groups (33.72 %) within 180 days after the first immunization. The antigen-specific binding antibodies started to increase at days 7 and reached their peaks at 10-14 days after the first immunization. The rapid and potent opsonophagocytic antibodies were also substantially above the background levels | ||
| 520 | |a CONCLUSIONS: rFSAV is safe and well-tolerated in patients undergoing elective surgery for closed fractures. It elicited rapid and robust specific humoral immune responses using the perioperative immunization procedure. These results provide evidence for further clinical trials to confirm the vaccine efficacy. China's Drug Clinical Trials Registration and Information Publicity Platform registration number: CTR20181788. WHO International Clinical Trial Registry Platform identifier: ChiCTR2200066259 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Closed fractures | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Staphylococcus aureus | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Gong, Mao-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hua-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, A-Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Zhao |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Shuang-Quan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiao-Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Jie-Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Jiang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Quan-Ming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 41(2023), 38 vom: 31. Aug., Seite 5562-5571 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:38 |g day:31 |g month:08 |g pages:5562-5571 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2023.07.047 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 38 |b 31 |c 08 |h 5562-5571 | ||